Categories: News

FH ORTHO, Recently Acquired by Olympus, Announces First Case Using e-ORTHO Shoulder Software

CENTER VALLEY, Pa., May 27, 2021 /PRNewswire/ — Today, Olympus Corporation of the Americas announced successful completion of a first use case of the 510(k) cleared e-ORTHO Shoulder software created by FH ORTHO, a company that Olympus acquired in November 2020. The case, conducted by Brian Schofield, MD, was an Arrow Prime shoulder replacement in which the next generation e-ORTHO 3D planning software was used for preoperative surgical technique planning.

FH ORTHO, a French company with a Chicago presence, has developed and manufactured innovative orthopedic implantable devices since 1964, focusing on joint reconstruction, ligament repair, biologics, foot and ankle devices and spine and trauma surgery solutions. In October 2020, the company received 510(k) clearance for its e-ORTHO planning software, which can save OR time by allowing physicians to more efficiently plan their surgical technique. The web-based e-ORTHO platform uses CT-scans of the entire scapula to construct a 3-D model of the anatomy to assist in preoperative surgical technique planning without the need for costly custom instruments often associated with software planning systems. With e-ORTHO, physicians can set the stage for improved techniques such as better implant positioning than without the templates and optimize inventory of implants in the OR, among other benefits.

While the e-ORTHO planning software cannot replace the expertise of a surgeon, physician users report realized value in the directional assistance the tool provides.

“We believe that this case may have saved OR time because of our pre-operative planning with e-ORTHO,” said Dr. Schofield of Schofield, Hand and Bright Orthopedics, Sarasota, Fl. “We look forward to continued use of the e-ORTHO system, which helps assist with optimizing glenoid adjustment, helps in adapting to the unique anatomical features of each patient, and could help a surgeon visualize a potential complication pre-operatively, while allowing for contingency planning to address potential complications.”

More information about FH Ortho is available at https://fhortho.com.

About Olympus

Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries.

Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit https://medical.olympusamerica.com/.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fh-ortho-recently-acquired-by-olympus-announces-first-case-using-e-ortho-shoulder-software-301301117.html

SOURCE Olympus Medical Systems Group

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

2 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

2 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

2 hours ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

2 hours ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

2 hours ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

2 hours ago